AbbVie (ABBV) Earning Somewhat Favorable Press Coverage, Analysis Shows
Media headlines about AbbVie (NYSE:ABBV) have trended somewhat positive on Wednesday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AbbVie earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.780652691899 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Toxoplasmosis – Global Market by Trends & Outlook with vendors AbbVie Inc, GlaxoSmithKline Plc, Novartis AG, Sanofi (medgadget.com)
- AbbVie’s Upadacitinib Gains Breakthrough Therapy Designation (finance.yahoo.com)
- Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ) (finance.yahoo.com)
- Ex-Dividend Alert: AbbVie Raised its Dividend by 11%; Will Trade Ex-Dividend on January 11, 2018 (finance.yahoo.com)
- Analysts’ Recommendations for Incyte in January 2018 (finance.yahoo.com)
AbbVie (ABBV) traded down $0.55 during trading on Wednesday, reaching $99.69. The company had a trading volume of 4,608,550 shares, compared to its average volume of 4,430,000. The firm has a market capitalization of $158,920.00, a price-to-earnings ratio of 24.20, a price-to-earnings-growth ratio of 1.20 and a beta of 1.53. AbbVie has a 12-month low of $59.27 and a 12-month high of $101.28. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45.
AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.39 by $0.02. The firm had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. AbbVie’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $1.21 earnings per share. sell-side analysts anticipate that AbbVie will post 5.55 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.85%. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date of this dividend is Thursday, January 11th. AbbVie’s dividend payout ratio (DPR) is 62.14%.
Several research analysts have recently issued reports on ABBV shares. Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price objective for the company in a research note on Tuesday, October 17th. BidaskClub cut AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 25th. Deutsche Bank raised their price objective on AbbVie to $88.00 and gave the stock a “hold” rating in a research note on Thursday, September 28th. Jefferies Group restated a “buy” rating and issued a $107.00 price objective (up from $94.00) on shares of AbbVie in a research note on Friday, September 15th. Finally, Vetr upgraded AbbVie from a “buy” rating to a “strong-buy” rating and set a $113.08 price objective for the company in a research note on Wednesday, December 20th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. AbbVie currently has an average rating of “Buy” and a consensus target price of $100.94.
In other AbbVie news, SVP Timothy J. Richmond sold 87,040 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the sale, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Henry O. Gosebruch sold 18,300 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $90.55, for a total value of $1,657,065.00. Following the completion of the sale, the insider now directly owns 81,287 shares in the company, valued at $7,360,537.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 494,676 shares of company stock worth $47,237,938. 0.23% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/abbvie-abbv-earning-somewhat-favorable-press-coverage-analysis-shows/1801816.html.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.